Mergers and Acquisitions

Nexelis to Acquire ImmunXperts, an Immunogenicity and Immune-Oncology Testing Lab

March 06, 2020

The acquisition will expand Nexelis’ immunology testing expertise.

Thermo Fisher Scientific to Acquire Qiagen for $11.5 Billion

March 05, 2020

The deal is expected to close during the first half of 2021.

Thermo Fisher Scientific Expands Specialty Diagnostics Portfolio with Acquisition

March 04, 2020

Thermo Fisher Scientific has announced that its acquisition proposal for Qiagen has been unanimously approved by the company’s managing board and board of directors.

Pivotal Acquires Patient Recruitment Specialist

March 04, 2020

Full-service contract research organization, Pivotal, has announced its acquisition of Akcelis, a Belgian company that specializes in patient engagement, recruitment, and retention.

Gilead to Acquire Immuno-oncology Company for $4.9 Billion

March 03, 2020

The acquisition will give Gilead access to Forty Seven’s investigational lead product candidate, magrolimab, a monoclonal antibody in clinical development for the treatment of numerous cancers.

Investments Inject Growth in Cell and Gene Therapies

March 02, 2020

The growing interest in developing cell and gene therapies has prompted industry investment to grow manufacturing capacity.

Takeda Acquires PvP Biologics for up to $330 Million

February 27, 2020

Takeda announced the acquisition after the conclusion of a Phase 1 study of the investigational medicine TAK-062 (Kuma062) for the treatment of uncontrolled celiac disease.

Eli Lilly Completes Acquisition of Dermira for $1.1 Billion

February 20, 2020

Through the agreement, Lilly will expand its immunology pipeline with lebrikizumab, Dermira’s novel, investigational mAb designed to bind interleukin-13 with high affinity.

Roche Completes Acquisition of Promedior for up to $1 Billion

February 14, 2020

Under the agreement, Roche will have access to Promedior's lead product candidate, PRM-15, a recombinant form of human pentraxin-2 that can possibly treat a range of systemic fibrotic diseases.

PCI Acquires Bellwyck to Expand its Clinical Trial Services

February 12, 2020

The acquisition will bring four new GMP-compliant facilities to the PCI network in the United States, Germany, and Canada.